Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfizer second-generation modRNA influenza vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pfizer's second-generation modified RNA (modRNA) influenza vaccine is an investigational nucleoside-modified messenger RNA vaccine candidate developed in partnership with BioNTech. It is designed to prevent influenza by delivering modRNA that encodes the hemagglutinin (HA) proteins of specific influenza virus strains. Once injected, the modRNA instructs host cells to produce these proteins, which then act as antigens to stimulate a protective immune response. This second-generation platform aims to improve upon the immunogenicity of earlier mRNA vaccine iterations and standard-of-care influenza vaccines. It is currently in Phase 2 clinical development (NCT06436703), where it is being evaluated as a trivalent vaccine in healthy adults aged 18 to 64 years.
- Other names
- influenza modRNA vaccine-Pfizer-influenzasecond-generation modRNA influenza vaccinePfizer-BioNTech modRNA influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Pfizer second-generation modRNA influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfizer second-generation modRNA influenza vaccine.